drugset
drugset / Trial / NCT04122560

Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration

NCT04122560 ↗

Phase 4 Completed 25 enrolled Radboud University Medical Center St. Antonius Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The pharmacokinetics of fluconazole are expected to be different in obese patients compared to non-obese patients. The investigators will determine fluconazole and free fluconazole concentrations in 16 obese patients and 8 healthy volunteers, who will receive oral and intravenous fluconazole in a semi-simultaneous design. A full pharmacokinetic curve will be obtained until 48 hours after intravenous administration.

Timeline

Start
2019-11-30
Primary completion
2021-03-23
Completion
2021-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule 400 mg Oral

Indications

candidiasis obesity disorder